Skip to content
OpenCapital
Get started

CRISPR Therapeutics CRSP Purchases of equity securities

Purchases of equity securities at other companies

TEC
Bio-TechneTECH
$15M—

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.33B+56.4%
Enterprise value$5.69B+69.8%
P/S1,298.3×+1,208×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireEquitySecuritiesFvNi.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's purchases of equity securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CRISPR Therapeutics's purchases of equity securities?
CRISPR Therapeutics (CRSP) reported purchases of equity securities of $4.62M in Q1 2026.
How has CRISPR Therapeutics's purchases of equity securities changed year-over-year?
CRISPR Therapeutics's purchases of equity securities decreased by 7.7% year-over-year, from $5M to $4.62M.
What does purchases of equity securities mean?
Cash spent purchasing equity securities for the investment portfolio.